BLRX

BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate Update

BioLineRx to Report First Quarter 2021 Results on May 26, 2021

BLRX Stock: From $4.88 To $5.18 (6.15% Increase) Pre-Market Explanation

BioLineRx Stock Is Trading Higher As Motixafortide-G-CSF Combo Shows Promise In Transplant Setting For Multiple Myeloma Patients

BLRX Stock: From $3.19 To $5.07 (58.93% Increase) Pre-Market Explanation

BioLineRx Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients